Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-arm Adaptive Group-sequential Trial Network in ALS (Lithium Carbonate vs Placebo)
2020-000579-19Phase 3Active
- Sponsor
- TRICALS
- Start
- Mar 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in amyotrophic lateral sclerosis (ALS) comparing Lithium carbonate with Placebo (2 arms). Primary endpoint: Overall survival. Started Mar 2021; status: active.
02
Drugs
lithium carbonate
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2020-000579-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000579-19.